Breaking News Headlines Today | Ground News

Cyber Week Sale - Get 40% off Vantage

decaturdailydemocrat.com image

News from decaturdailydemocrat.com

Yuma, United States

decaturdailydemocrat.com’s media bias is Lean Right. Ground News assigned this score by aggregating media bias ratings of a leanRight rating from Media Bias/Fact Check .

decaturdailydemocrat.com’s factuality rating is High. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about decaturdailydemocrat.com

Where is decaturdailydemocrat.com located?Yuma, United Statesdecaturdailydemocrat.com's Website

Media Bias Ratings

Average Bias Rating:

Lean Right

Lean Right

byMedia Bias/Fact Check

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top decaturdailydemocrat.com News

Zenocutuzumab-zbco (BIZENGRI®) Shows Durable Efficacy in Patients with Treatment-Naïve NRG1+NSCLC: Updated eNRGy Trial Results Presented at IASLC-ASCO NACLC

Maryland · Maryland

Zenocutuzumab-zbco (BIZENGRI®) Shows Durable Efficacy in Patients with Treatment-Naïve NRG1+NSCLC: Updated eNRGy Trial Results Presented at IASLC-ASCO NACLC

67% Center coverage: 18 sources

LEXINGTON, Mass., Dec. 6, 2025 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx), a private, fully-integrated biotechnology company, announced new data from a post hoc analysis of the Phase 2 eNRGy trial (NCT02912949) evaluating zenocutuzumab in patients with treatment-naïve non-small cell lung…See the Story

MENU - ORDER AI Announces Global Expansion with New Multilingual Capabilities, Supporting WHO Guidance on Dietary Needs for GLP-1 Users

GLP-1 · Wilmington

MENU - ORDER AI Announces Global Expansion with New Multilingual Capabilities, Supporting WHO Guidance on Dietary Needs for GLP-1 Users

70% Center coverage: 17 sources

New multilingual capabilities expand access to real-time GLP-1 dining guidance as WHO highlights the importance of protein-focused nutrition.See the Story

Vivacta Bio Announces Promising First-in-Human Results for GT801, an In Vivo CAR-T Therapy, in Non-Hodgkin's Lymphoma at the 2025 ASH Annual Meeting

Shanghai, China · Shanghai

Vivacta Bio Announces Promising First-in-Human Results for GT801, an In Vivo CAR-T Therapy, in Non-Hodgkin's Lymphoma at the 2025 ASH Annual Meeting

60% Center coverage: 15 sources

SHANGHAI, Dec. 6, 2025 /PRNewswire/ -- Vivacta Bio, a spin-off company of Grit Biotherapeutics advancing in vivo CAR-T therapies for oncology and autoimmune diseases, today announced encouraging initial data from an investigator-initiated, first-in-human study of GT801, a T-LNP/mRNA–based in vivo…See the Story

Breaking News Topics Related to decaturdailydemocrat.com